LockBody® Platform
Oncology
DiscoveryActive
Key Facts
About Centessa Pharmaceuticals
Centessa Pharmaceuticals, founded in 2020, consolidates specialized biotech assets under a unified, capital-efficient corporate structure with a patient-centric mission. Its primary achievement is advancing a pipeline of oral OX2R agonists, led by ORX750, which is in Phase 2 studies for narcolepsy and idiopathic hypersomnia, targeting a fundamental biological pathway for wakefulness. The company's strategy employs focused, data-driven development teams for each asset to rapidly progress programs, supported by a leadership team with deep industry and scientific expertise. A significant recent development is the announced acquisition by Eli Lilly, validating the platform's potential.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |
| Personalized Medicine Assays (Patient-Derived Explants) | Aurita Bioscience | Research-Use Only |
| CDK2-CyclinE1 & CDK2-CyclinA2 Assay | Aurora Biolabs | Commercial |
| POLQ & eIF4E Assay | Aurora Biolabs | Commercial |
| PKMYT1 & WEE1 Assay | Aurora Biolabs | Commercial |
| NTP42 | ATXA Therapeutics | Preclinical |
| Athebody® DARPins for pHLA-binding T-Cell Engagers | Athebio | Pre-clinical |
| Dual-Targeting CAR-T Programs | Factor Bioscience | Pre-clinical |